[go: up one dir, main page]

BRPI0811200A8 - Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina - Google Patents

Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina

Info

Publication number
BRPI0811200A8
BRPI0811200A8 BRPI0811200A BRPI0811200A BRPI0811200A8 BR PI0811200 A8 BRPI0811200 A8 BR PI0811200A8 BR PI0811200 A BRPI0811200 A BR PI0811200A BR PI0811200 A BRPI0811200 A BR PI0811200A BR PI0811200 A8 BRPI0811200 A8 BR PI0811200A8
Authority
BR
Brazil
Prior art keywords
heteroaryloxy
aryloxy
substituted
serotonin
dopamine
Prior art date
Application number
BRPI0811200A
Other languages
English (en)
Inventor
Liu Shuang
Allen Yang Yuh-Lin
Sambandam Aruna
F Molino Bruce
E Olson Richard
Original Assignee
Bristol Myers Squibb Co
Amr Tech Inc
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Amr Tech Inc, Albany Molecular Res Inc filed Critical Bristol Myers Squibb Co
Publication of BRPI0811200A2 publication Critical patent/BRPI0811200A2/pt
Publication of BRPI0811200A8 publication Critical patent/BRPI0811200A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS DE TETRA-HIDROBENZAZEPINAS ARILÓXI E HETEROARILÓXI-SUBSTITUÍDAS, COMPOSIÇÃO FARMACÉUTICA COMPREENDENDO OS REFERIDOS COMPOSTOS E O USO DOS MESMOS PARA BLOQUEAR A PERCEPÇÃO DE NOREPINEFRINA, DOPAMINA E SEROTONINA. A presente invenção refere-se aos compostos de derivados de tetra-hidrobenzazepina arilóxi e heteroarilóxi-substituído que são representados pelas fórmulas I (A-E) tendo a seguinte estrutura; onde o átomo de carbono designado * está na configuração R ou S, e os substituintes X e R1-R9 são conforme aqui definidos.
BRPI0811200A 2007-05-10 2008-05-08 Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina BRPI0811200A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91720007P 2007-05-10 2007-05-10
PCT/US2008/063043 WO2008141082A1 (en) 2007-05-10 2008-05-08 Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Publications (2)

Publication Number Publication Date
BRPI0811200A2 BRPI0811200A2 (pt) 2014-10-29
BRPI0811200A8 true BRPI0811200A8 (pt) 2015-09-22

Family

ID=40002594

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811200A BRPI0811200A8 (pt) 2007-05-10 2008-05-08 Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina

Country Status (14)

Country Link
US (1) US8987252B2 (pt)
EP (1) EP2146720A4 (pt)
JP (1) JP5566282B2 (pt)
KR (1) KR20100017767A (pt)
CN (1) CN101686982A (pt)
AU (1) AU2008251558B2 (pt)
BR (1) BRPI0811200A8 (pt)
CA (1) CA2685861A1 (pt)
CO (1) CO6420345A2 (pt)
EA (1) EA017308B1 (pt)
IL (1) IL201923A0 (pt)
MX (1) MX2009011922A (pt)
NZ (1) NZ580802A (pt)
WO (1) WO2008141082A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
EA020553B1 (ru) * 2009-05-12 2014-12-30 Олбани Молекьюлар Рисерч, Инк. 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2606049A4 (en) 2010-08-17 2014-01-08 Albany Molecular Res Inc 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE
CN103664974B (zh) * 2012-09-17 2016-12-21 中国科学院上海药物研究所 芳基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
ES2633981T3 (es) * 2012-12-26 2017-09-26 Sanwa Kagaku Kenkyusho Co., Ltd Nuevo derivado de benzoazepina y uso médico del mismo
WO2015161016A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
CN112209844A (zh) * 2020-10-22 2021-01-12 上海吉奉生物科技有限公司 一种3-甲氨基丙酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988690A (en) 1982-06-14 1991-01-29 Hoechst-Roussel Pharmaceuticals Inc. 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
JPS6394239A (ja) 1986-10-08 1988-04-25 Konica Corp 色素画像の安定性を改良したハロゲン化銀写真感光材料
YU155791A (sh) 1990-09-25 1994-01-20 Agouron Pharmaceuticals Inc. Antiproliferativna supstituisana triciklična jedinjenja
US5202319A (en) 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5416118A (en) 1992-04-09 1995-05-16 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6576664B1 (en) 1997-08-18 2003-06-10 Bristol-Myers Squibb Pharma Company Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6955873B1 (en) 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
WO2001055118A1 (en) 2000-01-26 2001-08-02 Ono Pharmaceutical Co., Ltd. Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
AU2003211951A1 (en) 2002-02-14 2003-09-04 Ono Pharmaceutical Co., Ltd. N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CN1812982B (zh) * 2003-06-26 2010-10-27 默沙东公司 苯并二氮杂*cgrp受体拮抗剂
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
CA2559611C (en) 2004-03-09 2012-01-17 National Health Research Institutes Pyrrolidine compounds
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
NZ565111A (en) * 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2011116663A (ja) 2008-05-30 2011-06-16 Otsuka Pharmaceut Co Ltd ベンゾジアゼピン化合物

Also Published As

Publication number Publication date
AU2008251558A1 (en) 2008-11-20
BRPI0811200A2 (pt) 2014-10-29
NZ580802A (en) 2012-09-28
EA017308B1 (ru) 2012-11-30
MX2009011922A (es) 2009-11-18
CN101686982A (zh) 2010-03-31
US20100210624A1 (en) 2010-08-19
AU2008251558B2 (en) 2012-12-20
EP2146720A1 (en) 2010-01-27
CO6420345A2 (es) 2012-04-16
EA200971045A1 (ru) 2010-06-30
JP2010527334A (ja) 2010-08-12
EP2146720A4 (en) 2012-01-18
CA2685861A1 (en) 2008-11-20
IL201923A0 (en) 2010-06-16
US8987252B2 (en) 2015-03-24
WO2008141082A1 (en) 2008-11-20
JP5566282B2 (ja) 2014-08-06
KR20100017767A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
BRPI0811200A8 (pt) Tetra-hidrobenzapinas arilóxi- e heteroarilóxi-substituídas e uso das mesmas para bloquear percepção de norepinefrina, dopamina, e serotonina
BRPI0613403A2 (pt) tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina
BRPI0811204A8 (pt) Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
BRPI0911243B8 (pt) derivados de benzofurano, benzotiofeno, benzotiazol, e composição farmacêutica
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
BR112014013661A2 (pt) Derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
EA201070451A1 (ru) Амидные соединения
DK2150530T3 (da) Substituerede sulfonamid-derivater
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
BRPI0601282A (pt) composição, e método de modificar a formação de hidrato de gás
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
ECSP088948A (es) 4-metil-1h-pirrol-2-carboxamidas 1,3-disustituidas y su uso para la producción de medicamentos
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
PA8579901A1 (es) Bifenilcarboxamidas sustituidas con n-aril piperidina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BRISTOL-MYERS SQUIBB COMPANY (US) , ALBANY MOLECUL

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]